3Batchelor TT,Sorensen AG,di Tomaso E,et al.AZD2171,a pan-VEGF receptor tyrosine kinase inhibitor,normalizes tumor vasculature and alleviates edema in glioblastoma patients[J].Cancer Cell,2007,11(1):83-95.
4Kamoun WS,Ley CD,Farrar CT,et al.Edema control by cediranib,a vascular endothelial growth factor receptor-targeted kinase inhibitor,prolongs survival despite persistent brain tumor growth in mice[J].J Clin Oncol,2009,27(15):2542-2552.
5Willett CG,Duda DG,di Tomaso E,et al.Efficacy,safety and biomarkers of neoadjuvant bevacizumab,radiation therapy,and 5-Fluorouracil in rectal cancer:a multidisciplinary phase II study[J].J Clin Oncol,2009,27(18):3020-3026.
6Heymach JV,Hanrahan EO,Mann H,et al.Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC[J].J Clin Oncol,2008,26(Suppl):a8009.
7Burstein HJ,Chen YH,Parker LM,et al.VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy[J].Clin Cancer Res,2008,14(23):7871-7877.
8Dowlati A,Gray R,Sandler AB,et al.Cell adhesion molecules,vascular endothelial growth factor,and basic fibroblast growth factor in patients with nonsmall cell lung cancer treated with chemotherapy with or without bevacizumab an Eastern Cooperative Oncology Group study[J].Clin Cancer Res,2008,14(5):1407-1412.
9Tannir NM,Zurita AJ,Heymach JV,et al.A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa:Clinical results and biomarker analysis[J].J Clin Oncol,2008,26(Suppl):a5093.
10Rini BI,Michaelson MD,Rosenberg JE,et al.Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma[J].J Clin Oncol,2008,26(22):3743-3748.